EUVIMEDEUVIMED entdecken
Crossref

Calcitonin Gene-Related peptide receptor antagonist suppresses allergic asthma responses via downregulation of group 2 innate lymphoid cells in mice

Erina Ike, Tasuku Kawano, Kento Takahashi, Tomomitsu Miyasaka, Tomoko Takahashi

International Immunopharmacology · 2023-09 · 122 · 110608

DOI: 10.1016/j.intimp.2023.110608 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2023-09. Verfasst von Erina Ike und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pathophysiology, Department of Pharmaceutical Sciences, Faculty of Pharmaceutical Sciences, Tohoku Medical and Pharmaceutical University,…. Hauptthemen laut MEDLINE: Immunity, Innate, Asthma. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Allergic asthma is caused by chronic inflammation and hyper-responsiveness of the airway and is thought to be mediated by adaptive T helper type 2 (Th2)-driven immunity. However, recent studies have demonstrated that neuropeptide calcitonin gene-related peptide (CGRP)-mediated activation of group 2 innate lymphoid cells (ILC2s) may contribute to the development of asthma pathogenesis. Here, we investigated the therapeutic effects of the systemic administration of rimegepant, a CGRP receptor antagonist, on allergic asthma. Hyperplasia of CGRP-immunoreactive pulmonary neuroendocrine cells (PNECs) was observed in ovalbumin (OVA)-induced asthmatic mice. Concomitant with this, we observed an increase in the content of total lung CGRP. Upon antigen challenge, the concentration of plasma CGRP was transiently upregulated, whereas CGRP immunoreactivity within PNECs was intensively downregulated, suggesting that PNECs were the most likely source of CGRP. When rimegepant was administered according to CGRP kinetics, it suppressed asthma phenotypes, including airway hyper-responsiveness, infiltration of inflammatory cells in bronchoalveolar lavage fluid (BALF), hyperplasia of mucus-producing cells, and production of the Th2 cytokine IL-5. Moreover, we observed a decrease in the number of ILC2s and their capacity for IL-5 release in the presence of IL-33 in rimegepant-treated mice. In the allergic asthma model, rimegepant suppressed the activation of ILC2s mediated by PNEC-derived CGRP and subsequently impaired adaptive Th2-driven immunity, which ameliorated asthmatic phenotypes. Thus, an anti-CGRP signal strategy to target ILC2 will be a novel and attractive approach for treating allergic asthma that is refractory to other treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunity, InnateAsthmaMiceAnimalsCalcitonin Gene-Related Peptide Receptor AntagonistsDown-RegulationInterleukin-5HyperplasiaLymphocytesLungCytokinesBronchoalveolar Lavage FluidCalcitonin Gene-Related PeptideMice, Inbred BALB COvalbumin

Stichwörter der Autor:innen

Allergic asthmaCGRPILC2PNECRimegepant

Substanzen

Calcitonin Gene-Related Peptide Receptor AntagonistsInterleukin-5CytokinesCalcitonin Gene-Related PeptideOvalbumin

Autor:innen und Institutionen

  • Division of Pathophysiology, Department of Pharmaceutical Sciences, Faculty of Pharmaceutical Sciences, Tohoku Medical and Pharmaceutical University, 4-4-1 Komatsushima, Aoba-ku, Sendai, Miyagi 981-8558 Japan.
  • Division of Pathophysiology, Department of Pharmaceutical Sciences, Faculty of Pharmaceutical Sciences, Tohoku Medical and Pharmaceutical University, 4-4-1 Komatsushima, Aoba-ku, Sendai, Miyagi 981-8558 Japan. Electroni…

Zitieren

APA

Ike, E., Kawano, T., Takahashi, K., Miyasaka, T., & Takahashi, T. (2023). Calcitonin Gene-Related peptide receptor antagonist suppresses allergic asthma responses via downregulation of group 2 innate lymphoid cells in mice. International Immunopharmacology, 122, 110608. https://doi.org/10.1016/j.intimp.2023.110608

Vancouver

Ike E, Kawano T, Takahashi K, Miyasaka T, Takahashi T. Calcitonin Gene-Related peptide receptor antagonist suppresses allergic asthma responses via downregulation of group 2 innate lymphoid cells in mice. International Immunopharmacology. 2023;122:110608. doi:10.1016/j.intimp.2023.110608

BibTeX
@article{Ike2023,
  author = {Ike, Erina and Kawano, Tasuku and Takahashi, Kento and Miyasaka, Tomomitsu and Takahashi, Tomoko},
  title = {Calcitonin Gene-Related peptide receptor antagonist suppresses allergic asthma responses via downregulation of group 2 innate lymphoid cells in mice},
  journal = {International Immunopharmacology},
  year = {2023},
  volume = {122},
  pages = {110608},
  doi = {10.1016/j.intimp.2023.110608}
}
Kostenlos starten →